Chemistry:Frunevetmab

From HandWiki
Short description: Feline medication for arthritis

Frunevetmab, sold under the brand name Solensia, is a medication used to treat pain associated with osteoarthritis in cats.[2]

It is the first monoclonal antibody new animal drug approved by the U.S. Food and Drug Administration (FDA) for use in any animal species.[2]

Frunevetmab is the international nonproprietary name (INN).[4]

Clinical usage

Frunevetmab is a cat-specific monoclonal antibody (a type of protein) designed to recognize and attach to a protein called nerve growth factor (NGF) that is involved in the regulation of pain.[2] When frunevetmab binds to NGF, it prevents the pain signal from reaching the brain.[2]

Frunevetmab is indicated for the alleviation of pain associated with osteoarthritis in cats.[2][3]

The most common side effects seen in cats include vomiting, diarrhea, injection site pain, scabbing on the head and neck, dermatitis, and pruritus (itchy skin).[2]

History

In February 2021, Frunevetmab was approved for medical use in the European Union.[3]

In January 2022, the following year, Frunevetmab was approved for medical use in the United States.[2][5]

Development as a potential drug for humans was stopped due to risk concerns over worsening osteoarthritis. [6]

See also

References

  1. "NADA 141-546 Solensia™ frunevetmab injection Injectable Solution Cats". animaldrugsatfda.fda.gov. Archived from the original on 15 January 2022. https://web.archive.org/web/20220115030222/https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/11817.  [bare URL PDF]
  2. Jump up to: 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 "FDA Approves Novel Treatment to Control Pain in Cats with Osteoarthritis, First Monoclonal Antibody Drug for Use in Any Animal Species". U.S. Food and Drug Administration (FDA) (Press release). 2022-01-13. Archived from the original on 2022-01-13. Retrieved 2022-01-14. This article incorporates text from this source, which is in the public domain.
  3. Jump up to: 3.0 3.1 3.2 "Solensia EPAR". 11 December 2020. https://www.ema.europa.eu/en/medicines/veterinary/EPAR/solensia.  Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  4. "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 78". WHO Drug Information 31 (3). 2017. 
  5. "Zoetis Announces FDA Approval of Solensia (frunevetmab injection) to Control Osteoarthritis Pain in Cats". Zoetis. 2022-01-13. https://news.zoetis.com/press-releases/press-release-details/2022/Zoetis-Announces-FDA-Approval-of-Solensia-frunevetmab-injection-to-Control-Osteoarthritis-Pain-in-Cats/default.aspx. 
  6. "FDA Approves Pain Reliever for Cats Considered Too Risky for Humans". 14 January 2022. https://www.painnewsnetwork.org/stories/2022/1/14/fda-approves-pain-reliever-for-cats-considered-too-risky-for-humans. 

 This article incorporates public domain material from the United States Department of Health and Human Services website https://www.fda.gov/.

Bibliography

External links